Avatrombopag for Thrombocytopenia in People With Cancer
Status:
Withdrawn
Trial end date:
2020-12-03
Target enrollment:
Participant gender:
Summary
This study will test whether avatrombopag is an effective treatment for thrombocytopenia in
people who have both cancer and a liver disease (such as cirrhosis, cholangitis, or
hepatitis). Researchers will look at whether giving participants avatrombopag for 3 weeks can
raise their platelet levels enough for them to begin chemotherapy. The study will also test
whether avatrombopag can continue to be effective against thrombocytopenia while participants
are on chemotherapy for 12 weeks or longer. In addition, researchers will determine how safe
the study drug is in participants.